Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 369 results:
Συντάκτης Τίτλος [ Τύπος] Έτος Φίλτρα: Συντάκτης is Polyzos, Stergios A [Clear All Filters]
Comparative effects of sibutramine and orlistat on weight loss, glucose metabolism and leptin levels in non-diabetic obese patients: A prospective study..
Indian J Endocrinol Metab. 16(1), 146-7.
(2012). Controlling the Impact of -Related Hyperhomocysteinemia on Neurodegeneration..
Medicina (Kaunas). 59(3),
(2023). Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis..
Metabolism. 154203.
(2020). Denosumab and bisphosphonates: rivals or potential "partners"? A "hybrid" molecule hypothesis..
Med Hypotheses. 77(1), 109-11.
(2011). Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers..
Metabolism. 64(10), 1291-7.
(2015). Denosumab treatment for juvenile Paget's disease: results from two adult patients with osteoprotegerin deficiency ("Balkan" mutation in the TNFRSF11B gene)..
J Clin Endocrinol Metab. 99(3), 703-7.
(2014). Diabetes mellitus: 100 years since the discovery of insulin..
Metabolism. 118, 154737.
(2021). Diagnostic approach to -related gastric oncogenesis..
Ann Gastroenterol. 35(4), 333-344.
(2022).
(2024). Dissociating nonalcoholic steatohepatitis from hepatocellular carcinoma in obesity..
Hepatobiliary Surg Nutr. 9(1), 73-76.
(2020). Dual-energy X-ray absorptiometry and quantitative ultrasound in patients with Paget's disease of bone before and after treatment with zoledronic acid: association with serum bone markers and Dickkopf-1..
J Clin Densitom. 13(2), 190-6.
(2010). The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation..
J Clin Endocrinol Metab.
(2021). Editorial: adiponectin in health and disease: current evidence and therapeutic perspectives..
Curr Med Chem. 19(32), 5425-6.
(2012). Effect of Helicobacter pylori eradication on hepatic steatosis, NAFLD fibrosis score and HSENSI in patients with nonalcoholic steatohepatitis: a MR imaging-based pilot open-label study..
Arq Gastroenterol. 51(3), 261-8.
(2014). The effect of leptin replacement on parathyroid hormone, RANKL-osteoprotegerin axis, and Wnt inhibitors in young women with hypothalamic amenorrhea..
J Clin Endocrinol Metab. 99(11), E2252-8.
(2014). The effect of pharmacological cessation and restoration of menstrual cycle on bone metabolism in premenopausal women with endometriosis..
Bone. 158, 116354.
(2022). Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease..
J Renin Angiotensin Aldosterone Syst. 12(4), 498-503.
(2011). Effect of spironolactone on pharmacological treatment of nonalcoholic fatty liver disease..
Minerva Endocrinol (Torino).
(2021). The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis..
Clin Endocrinol (Oxf). 72(6), 752-7.
(2010). The Effect of Trimebutine and/or Helicobacter pylori Eradication on the Gastroesophageal Reflux Disease, Irritable Bowel Syndrome, and Functional Dyspepsia Overlapping Disorders..
J Neurogastroenterol Motil.
(2019). Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial..
Diabetes Obes Metab. 19(12), 1805-1809.
(2017). Efficacy of Antiosteoporotic Medications in Patients With Rebound-Associated Fractures After Denosumab Discontinuation..
J Clin Densitom.
(2021). Emerging and future therapies for nonalcoholic steatohepatitis in adults..
Expert Opin Pharmacother. 17(14), 1937-46.
(2016). Emerging parameters relevant to the management of antimicrobial-resistant Helicobacter pylori infection..
Intern Med J. 52(9), 1654-1655.
(2022). Endocrine and metabolic disorders interplaying with non-alcoholic fatty liver disease..
Minerva Endocrinol. 42(2), 89-91.
(2017).